

# Danishuddin

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/11363029/danishuddin-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

8

papers

222

citations

6

h-index

9

g-index

9

ext. papers

297

ext. citations

5.7

avg, IF

3.79

L-index

#	Paper	IF	Citations
8	Descriptors and their selection methods in QSAR analysis: paradigm for drug design. <i>Drug Discovery Today</i> , <b>2016</b> , 21, 1291-302	8.8	147
7	Potential inhibitors designed against NDM-1 type metallo- $\beta$ -lactamases: an attempt to enhance efficacies of antibiotics against multi-drug-resistant bacteria. <i>Scientific Reports</i> , <b>2017</b> , 7, 9207	4.9	31
6	Designing of inhibitors against CTX-M-15 type $\beta$ -lactamase: potential drug candidate against $\beta$ -lactamases-producing multi-drug-resistant bacteria. <i>Journal of Biomolecular Structure and Dynamics</i> , <b>2018</b> , 36, 1806-1821	3.6	15
5	Development of Ligand and Structure-based classification models to design novel inhibitors against antibiotic hydrolyzing enzymes: Integration of web server. <i>Journal of Biomolecular Structure and Dynamics</i> , <b>2018</b> , 36, 2966-2975	3.6	8
4	Polycomb repressive complex 2 inhibitors: emerging epigenetic modulators. <i>Drug Discovery Today</i> , <b>2019</b> , 24, 179-188	8.8	8
3	Development and rigorous validation of antimalarial predictive models using machine learning approaches. <i>SAR and QSAR in Environmental Research</i> , <b>2019</b> , 30, 543-560	3.5	7
2	Computational Investigation Identified Potential Chemical Scaffolds for Heparanase as Anticancer Therapeutics. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	5
1	A decade of machine learning-based predictive models for human pharmacokinetics: Advances and challenges. <i>Drug Discovery Today</i> , <b>2021</b> ,	8.8	1